Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Rhea-AI Summary

Arbutus Biopharma Corporation has announced that it will release its third quarter 2023 financial results and corporate update on November 7, 2023. The press release is scheduled for 7:30 a.m. ET and the conference call/webcast will take place at 8:45 a.m. ET.

Positive

• Investors can expect to receive important financial information and updates on Arbutus Biopharma Corporation's performance in the third quarter of 2023. This can potentially positively impact the stock price if the results and updates exceed expectations.

Negative

• No negative takes identified.

WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2023 financial results and corporate update for Tuesday, November 7, 2023. The schedule for the press release and conference call/webcast are as follows:

•	Q3/2023 Press Release:	Tuesday, November 7, 2023 at 7:30 a.m. ET
•	Q3/2023 Conference Call/Webcast:	Tuesday, November 7, 2023 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran is the only RNAi that has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. We are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

 

FAQ

When will Arbutus Biopharma Corporation release its third quarter 2023 financial results and corporate update?

Arbutus Biopharma Corporation will release its third quarter 2023 financial results and corporate update on November 7, 2023.

What time is the press release scheduled for?

The press release is scheduled for 7:30 a.m. ET.

What time is the conference call/webcast scheduled for?

The conference call/webcast is scheduled for 8:45 a.m. ET.

Where can I access the live webcast of the conference call?

The live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

Will there be an archived webcast available after the event?

Yes, an archived webcast will be available on the Arbutus website after the event.